MI
IMDX

Motiv8 Investments’s Insight Molecular Diagnostics IMDX Stock Holding History

Motiv8 Investments’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$0 Buy
+10
New +$56 ﹤0.01% 961

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Motiv8 Investments's IMDX Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Insight Molecular Diagnostics (IMDX) in Q4 2025: 10 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #961 among its holdings.

35 funds tracked by Wall St. Rank hold IMDX as of Q4 2025.

  • Motiv8 Investments held 10 shares of Insight Molecular Diagnostics worth $0 as of Q4 2025.
  • Insight Molecular Diagnostics was a new Motiv8 Investments position in Q4 2025.
  • Insight Molecular Diagnostics made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #961 holding.
  • 35 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.